- Conditions
- Chin Retrusion
- Interventions
- JUVÉDERM VOLUMA® XC
- Device
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 14
- States / cities
- San Diego, California • Coral Gables, Florida • Miami Beach, Florida + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 10,865
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Renal Cell Carcinoma, Kidney Cancer
- Interventions
- bevacizumab, temsirolimus
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Covid19, Critical Illness, High Intensity Interval Training, ICU, Intensive Care Units, Fitness Trackers
- Interventions
- REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT), Comparator
- Behavioral · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Nashville, Tennessee
- Conditions
- Invasive Ductal Carcinoma, Ductal Carcinoma in Situ
- Interventions
- Intra-operative Radiation Therapy - IORT
- Radiation
- Lead sponsor
- Xoft, Inc.
- Industry
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2029
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Duarte, California • Long Beach, California + 17 more
- Conditions
- Androgen-insensitive Prostate Cancer
- Interventions
- MVA-BN-PRO
- Biological
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 7
- States / cities
- Homewood, Alabama • Washington D.C., District of Columbia • Lawrenceville, New Jersey + 4 more
- Conditions
- Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
- Interventions
- Vonoprazan, Placebo
- Drug
- Lead sponsor
- Phathom Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 776 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 108
- States / cities
- Athens, Alabama • Cullman, Alabama • Huntsville, Alabama + 94 more
- Conditions
- Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia
- Interventions
- EDIT-301
- Genetic
- Lead sponsor
- Editas Medicine, Inc.
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- Oakland, California • Minneapolis, Minnesota • New York, New York + 3 more
- Conditions
- Breast Cancer
- Interventions
- nivolumab, paclitaxel (PTX), nivolumab placebo, anthracycline, cyclophosphamide, Endocrine Therapy, Surgery
- Biological · Drug · Other + 1 more
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 521 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Greenbrae, California • Whittier, California + 27 more
- Conditions
- Respiratory Failure
- Interventions
- Written Checklist, Head of Bed Up
- Procedure
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • New Orleans, Louisiana • Nashville, Tennessee + 1 more
- Conditions
- Cutaneous T-cell Lymphoma
- Interventions
- romidepsin (depsipeptide, FK228)
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Stanford, California • Boston, Massachusetts + 3 more
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- CC-122, CC-223, Rituximab, CC-292
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 8
- States / cities
- Stanford, California • New Haven, Connecticut • Tampa, Florida + 5 more
- Conditions
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia
- Interventions
- MK-4208
- Drug
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Orange, California + 15 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Casdozokitug, Atezolizumab, Bevacizumab, Placebo
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Duarte, California • Los Angeles, California + 10 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- decitabine, azacitidine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Stanford, California • Stockton, California + 16 more
- Conditions
- Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Acalabrutinib, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Buffalo, New York • Columbus, Ohio + 3 more
- Conditions
- Huntington Disease
- Interventions
- Tominersen, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 25 Years to 50 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 15 more
- Conditions
- Radiation Exposure
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lung Transplant Rejection
- Interventions
- Belumosudil, Azithromycin, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Vaccination Refusal
- Interventions
- IVY
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 19
- States / cities
- Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more
- Conditions
- Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SHP465
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 4 Years to 12 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 48
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 43 more
- Conditions
- Melanoma
- Interventions
- glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab), glembatumumab vedotin and CDX-301
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Fort Myers, Florida + 10 more
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 647 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more